Navigation Links
Hiker without Human Heart Receives Heart Transplant 607 Miles Later
Date:11/15/2012

TUCSON, Ariz., Nov. 15, 2012 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that avid hiker Chris Marshall, who received the SynCardia temporary Total Artificial Heart in February, has been successfully bridged to a heart transplant at University of Washington (UW) Medical Center in Seattle.

(Photo: http://photos.prnewswire.com/prnh/20121115/LA13969)  

Watch video from NBC Seattle -

http://www.syncardia.com/News/avid-hiker-with-total-artificial-heart-receives-transplant.html

"I walked 607 miles with the Total Artificial Heart, so I was really fit going into that surgery," said Mr. Marshall, who received his heart transplant on Sept. 12. "That's very different from a lot of people who go into the transplant really sick. After the surgery, they not only have to recover from the transplant, but also from being sick for so long leading up to it."

Mr. Marshall was implanted with the SynCardia Total Artificial Heart on Feb. 6. Seven weeks later, on March 21, he became the first Total Artificial Heart patient in the Pacific Northwest to be discharged from the hospital using the Freedom® portable driver to power his Total Artificial Heart. After his discharge, Mr. Marshall hiked daily in the Seattle area with his wife Kathy and their golden retriever Gracie.

When asked what advice he has f
'/>"/>

SOURCE SynCardia Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Without Environmental Hygiene, Hand Hygiene Programs Fall Short in Reducing HAIs in Hospital Settings, Says UMF Corporation
2. LIVE VIA SATELLITE: Physician Demonstrates New Medical Technology to Combat Back Pain without Major Surgery
3. Man Without Human Heart Hikes More Than 400 Miles
4. Homecare Community Dismayed that Medicare Will Start Prior Authorization for Wheelchairs without a Clinical Template for Physicians to Document Need
5. RMANJ Research Demonstrates That Egg Freezing Prior To IVF Yields Positive Outcomes Without Increasing Risk Of Aneuploidy
6. Mount Sinai Medical Center 1st in Tri-State Area to Discharge Patient without Human Heart
7. Netsmarts Focus on Innovation to Help Health and Human Service Providers Span the Spectrum of Care in the Healthcare 3.0 Environment
8. SMT C1100 For Duchenne Muscular Dystrophy Moves To Human Testing
9. Global Human Vaccines Industry
10. ReproCELL Launches Alzheimers Disease Model Based on iPS-derived Human Neuronal Cells
11. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014   Ventana Medical Systems, Inc.  (Ventana), ... has entered into an agreement with Merck KGaA, Darmstadt, ... Serono in the United States ... Merck KGaA,s biopharmaceutical division on the development and commercialization ... using Ventana,s proprietary diagnostic assays. In alignment with Merck ...
(Date:7/10/2014)... , July 10, 2014 Decision Resources Group ... of the U.S. Food and Drug Administration,s (FDA) approval ... binder Velphoro, which was approved by the FDA in ... kidney disease (CKD) patients on dialysis. Other ... Nephrology (US) Q2 2014 : ...
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular ... has released its new range of elegant Quinceanera ... available at discounted prices. Worldwide clients can enjoy this ... the company’s online shop, there are plenty of beautiful ... with great materials. MyDressCity.com’s hot items are prom gowns, ...
(Date:7/13/2014)... A noninvasive optical imaging device developed at ... later occur in the brain and are a ... results from investigators conducting a clinical trial in ... July 15 in an oral presentation at the ... They also were invited by conference organizers to ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Wright & ... trial has been scheduled in July of 2015, in ... Lipitor lawsuits are in the discovery process in ... M. Gergel is presiding over the multidistrict litigation (MDL). ... on behalf of individuals who allege that they took ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 ECS ... who commented, “As a parent of a special needs ... need in the Seattle community for contemporary special education ... an important alternative to students and families in the ... practices and environment for special education. We welcome the ...
(Date:7/13/2014)... 13, 2014 According to The Peripheral ... a comprehensive program that teaches people how to deal ... without medications. This program also provides people with ... peripheral neuropathy , including numbness, prickling, burning, and intense ... that this home treatment program can help people eliminate ...
Breaking Medicine News(10 mins):Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:New Private School, Emerald City School, Founded in Downtown Seattle Now Accepting 1st to 6th Grade Students Who Learn Differently 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3
... do minor behavior problems and experiences early in life ... group of researchers has found that the answer may ... experiences lead to behaviors and new experiences that lead ... behavior. , The researchers found that children who had ...
... revenue exceeds $10 billion, COVINGTON, Ky. and ... ASH ) today completed its acquisition of Hercules,Incorporated, ... the world,s most essential needs and industries. Each ... $18.60 in cash and 0.093 of a,share of ...
... ... Business Assets, WAYNE, Pa., Nov. 13 Escalon Medical Corp.,(Nasdaq: ... ended,September 30, 2008., For the first quarter of fiscal 2009, ... fiscal 2007. This,included product revenue of $8,669,000 for the first quarter ...
... a leading,international manufacturer, marketer, and supplier of protective ... financial,results for the third quarter of 2008., ... were $265.2 million, an,increase of 8.2% over net ... of,2007. Excluding the impact of favorable foreign currency ...
... Inc. (Nasdaq: AMLN ) will be presenting at ... Wednesday, November,19, 2008 at 8:30 a.m. ET. Daniel M. ... be providing a corporate overview., The live presentation ... made,available following the event. The Web cast and recording ...
... N.J., Nov. 13 Pharmos Corporation,(Nasdaq: PARS ) ... Market ("Nasdaq") on November 11, 2008 that the Company ... requires the,Company to have a minimum of $2,500,000 in ... $500,000 of net income,from continuing operations for the most ...
Cached Medicine News:Health News:Cascading effect of even minor early problems may explain serious teen violence 2Health News:Ashland Completes Acquisition of Hercules 2Health News:Ashland Completes Acquisition of Hercules 3Health News:Ashland Completes Acquisition of Hercules 4Health News:Ashland Completes Acquisition of Hercules 5Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 2Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 3Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 4Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 5Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 6Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 7Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 8Health News:Pregis Announces Third Quarter 2008 Financial Results 2Health News:Pregis Announces Third Quarter 2008 Financial Results 3Health News:Pregis Announces Third Quarter 2008 Financial Results 4Health News:Pregis Announces Third Quarter 2008 Financial Results 5Health News:Pregis Announces Third Quarter 2008 Financial Results 6Health News:Pregis Announces Third Quarter 2008 Financial Results 7Health News:Pregis Announces Third Quarter 2008 Financial Results 8Health News:Pregis Announces Third Quarter 2008 Financial Results 9Health News:Pregis Announces Third Quarter 2008 Financial Results 10Health News:Pregis Announces Third Quarter 2008 Financial Results 11Health News:Pregis Announces Third Quarter 2008 Financial Results 12Health News:Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter 2
... Capture vital signs faster, easier, and ... LXi, the latest innovation in multi-parameter ... Spot LXi, you get more parameters ... flexibility to customize it to meet ...
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Medicine Products: